TickerGuard
Buy Day today: Neutral (52) Mixed market breadth · major macro event coming up
TLPH

Talphera Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

1.20$ -0.9% vs. previous close Closing price · As of: Sep 30, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet TLPH
Line item 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– – -36.1% -52.9% +497.9% +58.0% +70.5% -21.5% +47.9% -21.7% -24.4% +59.5% -24.2% -27.4% +17.5% -39.0% -57.1% -10.6% +63.0%
– – -38.3% -55.4% +560.1% +61.9% +69.3% -27.0% +55.9% -25.1% -28.8% +70.3% -33.6% -34.7% +7.8% -51.3% -53.0% -18.5% +121.9%
– – +17.8% -57.3% +155.1% +515.0% +84.4% -32.1% +79.8% -25.6% -34.1% +66.3% -83.3% +85.7% -71.9% +99.3% -62.5% +54.9% -33.5%
– – -37.9% -70.7% +871.9% +67.0% +73.5% -27.3% +50.6% -29.2% -24.7% +74.8% -37.4% -35.2% +8.7% -66.2% -40.5% -5.5% +130.0%
– – – – – – – – – +77.5% -73.7% -73.8% +7.7% +47.0% -74.8% +93.1% – – –
– – – – – – – – – +362.2% -55.6% -10.7% +285.8% -50.7% -31.7% +6.0% – – –
– – – – – – – – – – – – – – – – +0.0% +0.0% +0.0%
– – +20.5% +7.8% -67.9% +31.3% +20.2% +7.8% +138.1% +11.3% +6.4% +3.8% +14.2% -8.1% -6.8% -77.4% -75.5% +62.7% +23.9%
– – +32.7% +123.1% -41.5% +82.7% -52.1% +99.9% -6.9% -20.3% +34.0% +16.6% -14.5% +29.6% +5.0% -25.6% -67.2% -41.3% +43.9%
– – +66.3% +154.1% -68.3% +95.7% – – -32.1% -10.0% +118.7% +27.5% -49.1% +65.5% +0.1% -28.4% – – –
– – -22.8% -40.8% +181.8% +46.1% +4.7% +3.8% -35.8% -0.2% -8.6% +45.4% -16.9% +59.1% -22.5% -40.8% +6.4% -49.9% -18.8%
– – – – – – – – – – – – – -36.0% -61.9% – – – –
– – – – – +93.8% +116.1% -36.2% -29.0% -116.1% – – -1,073.9% – – – -35.3% -43.3% +112.9%
– – – – – – – – – – – – – – – – – – –
– +0.0% +0.0% +0.0% -15.7% +27.6% +79.6% +11.5% +0.3% +1.9% +3.5% +24.6% +35.6% +7.7% +40.6% +23.6% +92.6% +81.2% +64.1%

Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?